Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Non-Current Assets (2020 - 2025)

Insight Molecular Diagnostics' Other Non-Current Assets history spans 6 years, with the latest figure at $1.5 million for Q3 2025.

  • For Q3 2025, Other Non-Current Assets fell 11.76% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $1.5 million, down 11.76%, while the annual FY2024 figure was $691000.0, 49.24% up from the prior year.
  • Other Non-Current Assets for Q3 2025 was $1.5 million at Insight Molecular Diagnostics, up from $702000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.7 million in Q2 2021 and bottomed at $382000.0 in Q2 2022.
  • The 5-year median for Other Non-Current Assets is $1.7 million (2021), against an average of $1.4 million.
  • The largest annual shift saw Other Non-Current Assets tumbled 77.53% in 2022 before it surged 345.03% in 2023.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.7 million in 2021, then changed by 0.0% to $1.7 million in 2022, then crashed by 72.76% to $463000.0 in 2023, then surged by 49.24% to $691000.0 in 2024, then soared by 117.08% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Other Non-Current Assets are $1.5 million (Q3 2025), $702000.0 (Q2 2025), and $1.7 million (Q1 2025).